Eating Disorder Hope (“EDHope”) began as an independently operated educational website. Over time, it built credibility by publishing information about eating disorders and recovery, maintaining treatment directories and state and city provider pages, offering screening resources, and helping families identify possible sources of care.

That history gave the website something a new treatment company could not create overnight. That is, public trust, extensive searchable content, established Google visibility, and access to families actively looking for help.

Ownership and control of that platform changed in June 2026.

On June 30, Within Health announced that Hopeful Media, LLC, the operator of EDHope and The Bulimia Project, had become part of the Within Health organization. EDHope’s owner is now identified as Hopeful Media, LLC which is a wholly owned subsidiary of Within Health Group, Inc. Within Health is the brand name. Within Health Group, Inc. is the full corporate name identified by EDHope. The word “Within” by itself, has no particular significance.

Within Health is a for profit virtual eating disorder treatment company. EDHope, the educational website that spent years earning the public’s confidence is now owned and controlled by one of the virtual businesses competing for eating disorder patients.

The acquisition did not simply give Within Health another place to advertise. It gave the company access to families before they select a provider, before they understand the available levels of care, or before they recognize that the information presented to them might be shaped by a commercial interest which has only been in business since 2021. And does not see patients face-to-face.

From Education to Patient Acquisition

EDHope openly and notoriously continues to portray itself as an independent resource connecting families with treatment providers without favoring any particular program. Yet the contact number prominently advertised on its website routes callers directly to Within Health, the virtual treatment company that owns and controls EDHope.

That relationship is not disclosed beside the number in clear, prominent language. A visitor must instead notice and click the italicized phrase “*About Our Number,” which appears in small print beneath the telephone number. Those three words are inconspicuous on the page. Other hyperlinks are underlined, displayed in contrasting colors, or otherwise formatted to attract attention. The ownership related disclosure is not.

This ownership related disclosure is also hidden on another part of the EDHope’s homepage. EDHope merely states it is, “powered by Within.” Not owned, but powered by. Not Within Health. Just Within. Apparently, Within Health cannot even be completely transparent about its ownership of EDHope.

Only after the visitor opens the pop up does EDHope acknowledge the routing arrangement. Even then, the disclosure emphasizes that EDHope does not receive a commission based on the provider ultimately selected. That statement may sound reassuring, but it sidesteps the central financial conflict.

Within Health has no reason to pay a referral commission to its own corporate affiliate. When an EDHope caller enters treatment with Within Health, the economic benefit does not take the form of a commission. It arrives as treatment revenue generated by the patient’s admission.

The absence of a commission therefore does not eliminate the conflict. It merely describes the corporate arrangement in terms that obscure how the money is actually made.

Consider also more often than not, the person coming to the EDHope website is a frightened parent whose child may be suffering from a serious eating disorder and who is urgently trying to understand the illness, compare treatment options, and find help. EDHope expressly addresses families and loved ones, acknowledges that the treatment process can feel overwhelming, and invites visitors who do not know where to begin to call its advertised number. In those circumstances, a reasonable parent is likely to rely upon the website’s repeated assurances that EDHope is an independent, unbiased guide … and not stop to examine footer disclaimers, open inconspicuous hyperlinks, or trace the corporate ownership of Hopeful Media, LLC.

These companies do not publicly report how many calls become Within Health assessments, how many result in admissions, or how frequently callers are referred to competing inpatient, residential, or partial hospitalization programs. Without those figures, the public cannot determine whether the hotline functions as a neutral navigation service or as an admissions pipeline built upon the credibility EDHope developed before Within Health took control.

The distinction is especially important because Within Health only provides virtual treatment. Families calling an apparently independent resource should know whether they are receiving an objective assessment of every appropriate level of care or entering the admissions department of a virtual company selling one particular model.

A Marketplace Owned by One of Its Competitors

EDHope sells preferred directory visibility to treatment providers. Paying companies can appear above free listings, purchase premium placement, and obtain greater exposure across virtual, state, city, homepage, and other website locations.

This platform openly defines its users as a high-intent audience. In practical terms, this audience are families actively deciding where to obtain treatment and how to spend substantial amounts of money.

Competing providers are therefore being asked to purchase visibility inside a marketplace owned and manipulated by Within Health. Even after paying, no competitor can obtain the advantages Within Health already possesses through ownership of the website, access to its total audience, receipt of its treatment calls, and potential knowledge of the searches and provider pages attracting consumers.

Within Health is also identified as EDHope’s Platinum Sponsor. That description makes Within Health sound like an outside advertiser supporting an independent publication, even though its wholly owned subsidiary operates the publication.

The owner is not merely buying space inside the marketplace. The owner controls the marketplace itself.

The Owner Declares Itself Superior

EDHope’s sponsorship page describes Within Health’s treatment as “clinically superior” and “revolutionary.” Those phrases appear on a website that continues to present itself as an independent source of treatment information.

“Clinically superior” is not harmless puffery. It is a comparative medical claim suggesting that Within Health produces better clinical results than competing treatment approaches.

The advertisement does not identify the programs being compared, the outcomes measured, the patient population studied, the methodology used, or any independent research supporting the claim. Within Health may possess such evidence, but none is provided beside the assertion.

The conflict of interest and ethical questions are difficult to ignore. A virtual treatment company controls the website, appears as its highest-level sponsor, and uses the platform to declare its own services clinically superior.

Paid Placement Disguised as Distinction

EDHope uses the heading “Top Virtual Eating Disorder Centers” above a tier containing sponsored providers. Its advertising materials separately confirm that payment buys placement above free listings and that premium payment can secure top positioning.

The word “Sponsored” appears beside the paid providers, but the heading still communicates a broader message. A family may reasonably interpret “Top” to mean that the programs were selected because of superior outcomes, safety, experience, or independent clinical review. The public materials disclose no such ranking methodology. What they do establish is that money materially influences prominence.

A sponsored provider has purchased attention. A top provider is generally understood to have earned distinction. EDHope blurs that difference while placing its own corporate owner inside the preferred tier.

And the money continues to flow into the same interconnected network. Providers may purchase premium placement on EDHope, but callers using the website’s general treatment number are delivered first to Within Health. When a caller needs in-person care that Within Health cannot provide, the most obvious referral destination is Galen Hope, the South Florida treatment center founded and still led by Within Health’s own co-founder, chief executive officer, and chief medical officer, Dr. Wendy Oliver-Pyatt.

Within Health and Galen Hope do not publicly disclose whether Galen Hope receives preferential referrals, what instructions are given to admissions personnel, or how often callers are directed there rather than to unaffiliated competitors. It would strain credulity to assume that these overlapping leadership, clinical, and commercial relationships play no role in the referral process. That does not establish the answer. It does establish why the FTC should obtain the call scripts, referral logs, internal communications, financial arrangements, and admissions data necessary to find it.

Competitors Vanish While Their Names Remain

EDHope’s provider directory is not comprehensive. Major treatment organizations have been excluded from relevant searches, substantially underrepresented, or connected to pages containing little or no useful information.

Eating Recovery Center operates a large Dallas based program offering inpatient, residential, partial hospitalization, and intensive outpatient treatment. Yet EDHope’s Dallas results have prominently displayed sponsored Center for Discovery locations while failing to present ERC Dallas as a functioning local option. ED Hope nevertheless maintains an indexed page using the name “Eating Recovery Center Dallas.” But this page contains no meaningful provider name, address, telephone number, description, or treatment information.

Children’s Hospital of Plano which has a dedicated eating disorder treatment program for children and adolescents is also absent from EDHope’s Texas treatment centers.

Center for Change also had an indexed page bearing its name but no usable listing. An obsolete Veritas Collaborative page remains searchable even after that brand had been retired and consolidated under The Emily Program.

These pages may be the result of neglect, faulty migration, outdated databases, or deliberate commercial strategy. The public record does not yet establish which explanation is correct. Their practical effect is easier to identify. A consumer searching for a particular treatment provider can enter a Within Health owned website, encounter paid listings and Within Health advertising, and receive an invitation to call Within Health, while the organization originally sought is nowhere meaningfully presented.

When questionable health claims are being made and families are potentially hurt, the ramifications are serious.  As should be the consequences.

The Partner Who Understood the Internet

Within Health’s digital strategy becomes easier to understand when its leadership is examined. The company’s co-founder and president, Abhilash Patel, publicly describes himself as a digital marketer, entrepreneur, and venture investor.

His Within Health biography states that he founded Ranklab, a marketing company that worked with behavioral health operators, and co-founded Recovery Brands, the digital publisher associated with Rehabs.com and Recovery.org. Patel’s experience lies precisely at the intersection of behavioral health, internet publishing, search visibility, and patient acquisition.

That background does not prove that Patel created the empty competitor pages or directed deceptive advertising. It does establish that Within Health was co-founded by an executive who understood the commercial value of controlling the websites families encounter before choosing treatment.

EDHope is far more than a collection of educational articles. It functions as a powerful patient acquisition channel, intercepting consumers who are searching for specific eating disorder treatment programs and instead, directs them first to an EDHope controlled page. Across numerous Google searches, EDHope appears as the first organic result, often outranking the treatment provider’s own website. The following searches illustrate the pattern:

Iaedp eating disorders

AED eating disorders

Veritas eating disorders

Center for Change eating disorders

Monte Nido eating disorders

Center for Discovery eating disorders

Odyssey eating disorders

Crescent Grace eating disorders

Avalon Hills eating disorders

With those searches, and many others, the result you receive is more than likely, this:

The value of the first organic search result is not theoretical. Approximately 28% of Google users click it. That visibility gives EDHope access to consumers at the precise moment they are searching for treatment. Because Within Health operates a virtual treatment program and shares founding leadership and executive control with Galen Hope, an in person provider, EDHope functions as the front door to an affiliated treatment network. Each caller or website visitor is therefore more than a reader seeking information. That person is a prospective patient capable of generating significant treatment revenue.

The Certification Operation Completes the Network

The Within Health system now extends beyond treatment, media, and referrals. The Eating Disorders Education Institute is developing and issuing the Eating Disorders Certified Specialist (“EDCS”) designated credential.

Within Health executives and clinical leaders teach through the institute. Their instructor pages already display the EDCS credential after multiple names, even though the institute’s public materials identify September 2026 as its official launch.

A legitimate pilot program or faculty credentialing process may explain that timing. The institute has not publicly provided enough information to determine who established the standards, who independently evaluated the first recipients, or whether affiliated personnel received special pathways.

The broader conflict is more significant. A treatment network can now participate in educating clinicians, define professional standards, award credentials, and employ some of the people displaying those credentials.

Without independent governance and transparent validation, the process becomes circular. Affiliated individuals create the standards, teach the curriculum, award the credential, and then use the resulting designation to strengthen the authority of affiliated treatment services.

Peeling Back the Layers

On the surface, the organizations initially appear separate. Within Health provides virtual treatment, Hopeful Media operates websites, EDHope publishes information and directories, EDEI provides professional education and certification, and Galen Hope provides in-patient treatment services.

However, if we follow the leadership, one person connects every major component.

Dr. Wendy Oliver-Pyatt is Within Health’s co-founder, chief executive officer, and chief medical officer.

The Eating Disorders Education Institute is the public-facing educational operation of Institute for Contemporary Eating Disorder Education, LLC, a Florida for profit LLC owned and controlled by Dr. Wendy Oliver-Pyatt, its only publicly identified authorized member.

Galen Hope is a privately held, for profit treatment company operated through Galen Hope Holdings, LLC. It was founded and originally owned by Dr. Oliver-Pyatt and Amy Boyers. Dr. Oliver-Pyatt is listed on the entity’s website as its CEO and Founder.

Within Health’s subsidiary, Hopeful Media, LLC controls EDHope. EDHope promotes Within Health, routes treatment calls to Within Health, and describes Within Health’s services as clinically superior. Current Within Health personnel teach through Dr. Oliver-Pyatt’s certification institute.

Patel provides the digital marketing and behavioral health publishing experience. Dr. Oliver-Pyatt supplies the medical authority, executive control, treatment operations, and certification enterprise.

Together, they sit at the center of a network syndicate capable of influencing what families read, which providers they find, whom they call, and which professionals appear qualified to treat them.

An Investigation Is No Longer Optional

This structure may ultimately prove to be aggressive but lawful vertical integration. It also may instead represent one of the most concentrated and conflicted commercial systems in the eating disorder field.

The conduct described above raises several potential violations of Section 5 of the Federal Trade Commission Act which prohibits unfair or deceptive acts or practices in commerce.

Despite its ownership by Within Health and the routing of its general treatment telephone number to Within Health, EDHope’s continued representation as an “independent and unbiased educational resource” may create a materially misleading impression about the commercial source and purpose of the information families receive.

The FTC expressly recognizes that promotional content may be deceptive when it appears to originate from an independent or impartial source, even when some underlying statements are technically accurate. Similarly, placing paying providers beneath a heading such as “Top Virtual Eating Disorder Centers” may falsely imply that prominence was earned through objective clinical evaluation rather than purchased through sponsorship.

Within Health’s description of its treatment as “clinically superior” presents an additional issue because an objective comparative health claim must be supported before publication by competent and reliable scientific evidence relevant to the precise comparison being asserted. Disclosures that the website is “powered by” Within Health, that certain listings are sponsored, or that calls are directed to Within Health will not necessarily cure these representations if the disclosures are inconspicuous, separated from the claims, or overwhelmed by the website’s broader portrayal of independence.

The FTC evaluates the entire net impression conveyed to a reasonable consumer, making the ownership relationship, paid rankings, treatment-call routing, and asserted clinical superiority appropriate subjects for investigation as possible deceptive misrepresentations, material omissions, and inadequately substantiated health advertising.

The FTC will be asked to investigate those matters as well as the claims of independence, the routing and conversion of treatment calls, the assertion of clinical superiority, the paid provider rankings, the use of competitor-name pages, the handling of consumer search and health-related data, and the relationships among Within Health, Hopeful Media, Eating Disorder Hope, Galen Hope, and the Eating Disorders Education Institute.

The central question is no longer whether each company performs some legitimate function. The question is whether those functions have been assembled into a coordinated system that converts public trust, internet visibility, professional authority, and consumer vulnerability into an unfair and unethical commercial advantage.

Families have a right to believe they are entering an independent educational resource. If instead, they are entering into a privately controlled treatment network hiding behind the reputation of a website built before that network owned it, there should be draconian consequences for this misconduct.

Dr. Oliver-Pyatt and the executives surrounding these enterprises are now on notice. The ownership records, leadership overlaps, paid rankings, comparative clinical claims, treatment-call routing, competitor-name pages, and prematurely displayed credentials have been identified and are subject to subpoena.

The remaining questions cannot be answered through carefully drafted website disclosures or assurances of editorial independence. They require the underlying call scripts, referral logs, admissions data, internal communications, credentialing records, financial relationships, and instructions given to employees who are contacted by families seeking treatment.

Presumably, the Federal Trade Commission and other appropriate agencies who may conduct investigations will be requesting those records. Perhaps only then will truthful answers be forthcoming from the syndicate of Within Health, Galen Hope, Hopeful Media, EDHop, Eating Disorders Education Institute and Dr. Wendy Oliver-Pyatt.

The eating disorder field urgently needs better professional education. Physicians, nurses, therapists, and dietitians may complete years of training without learning how to recognize malnutrition, assess medical instability, identify refeeding risk, distinguish among diagnoses, or determine when outpatient treatment has become unsafe.

The Eating Disorders Education Institute (“EDEI”) is the latest entity attempting to provide this education by claiming its program would build bridges. Instead, it merely created yet another silo pandering to a certain aspect of the eating disorder spectrum.

The EDEI was created by Chevese Turner and Dr. Wendy Oliver-Pyatt. The EDEI purportedly offers courses in assessment, medical complications, psychological treatment, nutrition, trauma, cultural awareness, weight stigma, body liberation, and social justice. It also plans to award a new Eating Disorders Certified Specialist credential known as EDCS.

The question is not whether additional education would benefit clinicians. The question is why the field needed another privately controlled, for profit credential, particularly one that places social justice and body liberation so prominently within its definition of professional competence.

An unproven credential marketed as a new standard

EDEI describes itself as a leading certification program. This despite the fact that its first public cohort is not scheduled to begin until September 2026. The credential therefore has no record of graduates, examination performance, employer acceptance, disciplinary enforcement, or improved patient outcomes.

New programs must first be required to prove themselves. They cannot credibly market anticipated success as an established accomplishment.

Even the current public materials of this “institute” (which really is not an institute at all) provide inconsistent descriptions of what candidates must complete. Different pages refer to varying numbers of courses and either eighteen or twenty-four practicum hours. Those discrepancies may be prelaunch mistakes, but they concern the essential requirements of a credential already being promoted as evidence of specialization and clinical readiness. They also evidence haste and lack of thorough professionalism.

A certification body must be able to state clearly how many courses are required, how much supervised experience candidates must obtain, what knowledge is tested, and what the designation actually certifies. The EDEI fails on these issues.

Social justice is not merely included; it is embedded

EDEI’s curriculum contains legitimate clinical subjects, including assessment, medical complications, psychological treatment, nutrition, trauma, and ethics. Topics which are covered by other programs. It would be inaccurate to describe the EDEI as nothing more than social activism.

Yet a number of core courses expressly emphasize cultural awareness, weight stigma, body liberation, social justice, and culturally responsive care. EDEI also states that weight inclusivity, anti-bias practice, cultural humility, and diverse lived experience will be integrated throughout the program.

Some of that instruction is necessary. Clinicians often miss eating disorders in people who do not appear underweight, and patients in larger bodies can suffer severe restriction, malnutrition, and medical instability. Cultural and economic barriers can also prevent people from obtaining accurate diagnoses and treatment.

The difficulty arises when broad political or philosophical concepts are treated as settled clinical competencies. Body liberation and social justice are not medical diagnoses, treatment protocols, or measurable safety standards. EDEI must clearly distinguish among replicated research, clinical guidelines, expert opinion, lived experience, and advocacy doctrine.

Lived experience can reveal mistreatment and diagnostic blind spots. But it does not carry the same evidentiary weight as validated clinical research, particularly when patients with the same diagnosis may hold sharply conflicting views about treatment.

And most importantly, instead of simply illuminating these issues, the EDEI must provide practical, rational, logical, workable, real-life solutions addressing these issues. Without solutions to embrace and implement, illumination becomes nothing more than complaining.

Certification should measure competence, not agreement

EDEI emphasizes reflective “Confirm Understanding” exercises, while its public materials provide little detail about the final examination or competency assessment. Reflection can help students examine assumptions, but it cannot by itself establish that a clinician recognizes bradycardia, electrolyte abnormalities, orthostatic instability, prolonged QTc, suicide risk, or refeeding syndrome.

Those subjects have clinically sound and clinically dangerous answers. A specialist credential must be capable of failing an applicant who does not understand them.

The reverse is equally important. A clinician who demonstrates competence in diagnosis, medical risk, nutritional rehabilitation, family involvement, and evidence-based treatment should not be penalized because the clinician questions body liberation, HAES doctrine, or a particular interpretation of social justice.

EDEI should disclose its examination blueprint, passing standard, validation process, retesting policy, and method for evaluating reflective assignments. Candidates should also receive an explicit assurance that respectful disagreement with contested social theories will not jeopardize certification.

Otherwise, EDCS risks becoming a measure of ideological alignment and not clinical education.

Why was another credential necessary?

EDEI is not entering an empty field. iaedp already administers the Certified Eating Disorder Specialist credential, or CEDS, which requires eating disorder specific clinical experience, consultation, education, examination, and professional references.

Iaedp’s governance, financial incentives, and former membership and symposium requirements remain legitimate subjects of criticism. Those problems do not erase the fact that CEDS is an established credential with published experience requirements.

The Inclusive Eating Disorder Specialist credential, or IEDS, also recently entered the market. That program heavily emphasizes weight inclusive, trauma informed, antiracist, HAES aligned, and social justice-based education. It mentions White Supremacy Culture or WSC approximately 175 times in one module alone. It has seemingly cornered the market on social justice drum banging.

EDEI therefore does not apparently duplicate an established clinical credential. It also duplicates much of the ideological territory already claimed by IEDS.

So, what does EDCS teach or measure that CEDS and IEDS do not? Does it explore newer biologically based treatment regimens like rTMS? Does it explore the manner in which social media platforms cause harm and what can be done to minimize exposure to dangerous on-line content? Does it explore the exploding access to AI platforms and their influence on patients? Does it explore revolutionary brain implants?

What patient harm resulted from the absence of a third designation which needed to be addressed? Did Ms. Turner and Dr. Oliver-Pyatt attempt to improve, supplement, or collaborate with either existing program? Could EDEI’s courses have become an advanced concentration within an established credential? Why didn’t the ecosystem finally come together, place families first and collaborate on this important topic? This would have resulted in the production and acceptance of one, all-encompassing, strong, wide-ranging certification program which would have been authoritative, respected and the cornerstone of a stronger, collaborative community

It is reasonable to presume that EDEI will not publicly answer those questions. For that matter, will anyone else in the community?

Without a formal gap analysis or evidence of failed collaboration, EDEI appears to follow a familiar pattern within the eating disorder ecosystem: leaders identify self-perceived deficiencies in an existing organization and respond by creating another organization they can control.

A field that teaches collaboration while practicing fragmentation

Eating disorder care depends on collaboration among medicine, psychiatry, psychology, nutrition, nursing, patients, and families. A failure to communicate across those disciplines places patients in danger.

However, at the institutional level, the field repeatedly models the opposite conduct. Iaedp has CEDS. Inclusive Eating Disorder Education has IEDS. EDEI is introducing EDCS and its own consultant pathway. With no oversight and no federal or state agency which can impose accountability and consequences, silo mentality has become the inevitable result. The cost for this short sightedness is measured in human lives taken.

Each organization controls its curriculum, eligibility requirements, assessments, instructors, directories, badges, renewal fees, and professional network. No independent national body determines whether the credentials are equivalent, complementary, redundant, or incompatible. This proliferation does not create a common understanding of eating disorders. It allows clinicians to select the credential that most closely reflects their existing beliefs.

Patients and families are then left to decipher the difference between CEDS, EDCS, and IEDS. The similarity between CEDS and EDCS is especially troubling because the same four letters are merely rearranged, increasing the possibility of confusion among patients, employers, referral sources, and insurers.

Collaboration forces competing disciplines and philosophies to confront their blind spots. Separate institutions populated by generally aligned faculty can reinforce confidence without producing a more complete understanding.

The resulting fragmentation also weakens advocacy. Legislators, medical schools, licensing boards, and healthcare systems need a defensible statement of what every professional should know about eating disorders. A field divided among competing credentials and ideological definitions cannot provide that baseline with authority.

Instead of financing another badge, the ecosystem should be developing a common national competency framework that can inform medical education, graduate training, licensing requirements, and continuing education.

Closing the conversation compounds the problem

Ms. Turner and other social advocates have blocked people who disagree with them on social media. This is very troubling since it results in substantive questions being excluded from discussions used to promote professional education. Blocking critics removes contrary views from the conversation visible to followers and can create an artificial appearance of consensus. Blocking opposing points of view is not progress. To the contrary.

The question must be posed, why should a “president” of an organization which is supposed to be operating for the good of families suffering from eating disorders block anyone? How does that serve the interests of the community? As “president” of EDEI, Ms. Turner’s first and highest obligation is to the eating community at large. That includes ALL the community. Which leads to consideration of a broader issue. And that is whether that exclusion extends to clinicians, families, researchers, and advocates who question EDEI’s ideology, standards, or need for another credential. How far is she prepared to go?

A certification body should welcome rigorous examination. Scientific disagreement is not harassment, and clinical questioning is not exclusion.

EDEI could answer all concerns through transparency. Before awarding EDCS, it should publish one definitive set of course and practicum requirements, specify how much eating disorder specific experience candidates need, disclose its testing and disciplinary procedures, and explain how its founding instructors received the credential before the public launch.

The EDEI should also publish a comparison showing what EDCS adds to CEDS and IEDS, identify any attempts at collaboration, and explain why another separately controlled credential was necessary. Candidates should be told that reflective work will be judged by reasoning and evidence rather than ideological agreement.

Most importantly, EDEI should consider whether its curriculum could contribute to an independently administered national standard rather than another proprietary system. Different organizations could continue offering specialized instruction while sharing one minimum definition of eating disorder competence.

EDEI is introducing an untested designation with inconsistent public requirements, uncertain independent validation, substantial overlap with existing programs, and an unusually prominent social justice orientation. At the same time, the field continues to lack a common standard that patients, employers, medical schools, and policymakers can understand.

EDEI’s slogan is “Building Bridges, Changing Lives.” A bridge should connect existing institutions and bodies of knowledge. It should not merely lead to another separately controlled credential.

If it does not do that, EDEI is not any type of bridge.  It is simply another silo.

Alsana’s Manufactured Medical Authority

Alsana represents its Chief Medical Officer, Dr. Jay Joglekar, as a “leader in the eating recovery industry” who oversaw five residential, partial hospitalization and intensive outpatient programs in the Washington, D.C. region. Alsana also claims that he works with its clinical and admissions teams and “reviews each client’s pre-admission medical assessments.”

These representations are intended to convey expertise, vigilance and safety. Families deciding whether to entrust a medically compromised loved one to Alsana are expected to believe that an experienced eating disorder physician personally evaluates every prospective patient before admission.

The public record provides no reasonable basis for that belief.

A Specialist Who Exists Only in Alsana’s Biography

Alsana does not identify any of the five programs Dr. Joglekar supposedly oversaw. It names no employer, treatment center, location, period of service or formal position. The company offers no description of his responsibilities and does not even establish that the programs treated eating disorders.

That omission is glaring. Treatment programs have names, licensed facilities have addresses, and physicians who lead residential, PHP and IOP programs ordinarily leave an identifiable professional record. Yet Alsana’s entire basis for calling Dr. Joglekar an eating recovery industry leader appears to be a sentence Alsana wrote about its own employee.

Independent records describe a very different professional background. Dr. Joglekar’s Privia profile identifies him as an internal medicine physician in Winchester, Virginia who graduated from the University of West Indies Medical School. It discusses internal medicine, integrative medicine, electronic medical records and earlier work involving a clinical trial for head and neck cancer. It contains no reference to anorexia nervosa, bulimia nervosa, ARFID, medical stabilization, refeeding complications or leadership of an eating disorder program.

His Virginia Board of Medicine profile also identifies internal medicine as his area of practice. According to the most recent updates, he reported practicing internal medicine at Internal Medicine Consultants in Winchester from Monday through Friday. His profile lists no eating disorder facility, behavioral health appointment, academic position or specialized role involving eating disorders.

Public searches have identified no article written by Dr. Joglekar about eating disorders, no professional presentation, no eating disorder research project and no federal research award in the field. There is no publicly visible affiliation with the Academy for Eating Disorders nor iaedp, no documented role with NEDA and no disclosed eating disorder credential or certification.

A physician does not need to write articles, receive federal grants or join professional organizations to provide competent care. But Alsana is not merely stating that Dr. Joglekar is a licensed internist. It is presenting him as a leader in a specialized field while identifying no employment, training, clinical experience, scholarship or professional involvement that supports that description.

The cumulative absence cannot be dismissed as an incomplete résumé. Alsana supplies the conclusion while omitting every fact that could establish its truth. That is not transparency. It is credentialing by assertion.

Internal Medicine Is Not Eating Disorder Expertise

Dr. Joglekar may be a capable internist. Internal medicine training is relevant to cardiac abnormalities, electrolyte disturbances, dehydration, kidney function, endocrine complications and medication interactions. None of that, however, establishes specialized competence in evaluating patients entering a higher level of care for an eating disorder.

Such an admission is not a routine medical clearance. Patients can appear outwardly stable while facing serious cardiac, metabolic and psychiatric danger. Laboratory results may appear deceptively normal, current weight may conceal rapid deterioration, and a single set of vital signs may fail to reveal fluid manipulation, purging or the cumulative effects of severe restriction.

A meaningful review requires the physician to integrate weight trajectory, blood pressure, pulse, orthostatic changes, laboratory findings, EKG results, medications, purging, restriction, compulsive exercise, psychiatric instability and refeeding risk. The physician must also determine whether the proposed facility can safely manage the patient or whether acute medical hospitalization is required.

Nothing publicly available establishes that Dr. Joglekar has experience making those decisions in eating disorder patients. His general medical background may qualify him to read laboratory results and identify familiar abnormalities. But Alsana has shown no factual basis for portraying him as an authority on the complex and frequently deceptive medical presentation of patients entering residential treatment, PHP or IOP.

Without specialized experience, his review would necessarily depend heavily on the work of Alsana’s nurses and admissions personnel, the company’s standardized protocols and the information selected for his consideration. That is not the independent medical safeguard families are led to believe they are receiving. It is a corporate admissions process carrying a physician’s name.

What Does “Reviews Each Client” Actually Mean?

Alsana’s use of the word “reviews” conceals more than it reveals. The term could mean that Dr. Joglekar personally examines every original record, independently interprets the medical findings, evaluates the patient’s stability and determines whether the proposed placement is safe. It could just as easily describe a process in which a nurse summarizes the file, identifies selected abnormalities and obtains an electronic approval from the physician.

Those processes are not remotely equivalent. A checklist is not an individualized medical evaluation, a nursing summary is not an independent physician analysis, and an electronic signoff does not establish that the physician considered the complete clinical picture.

Alsana nevertheless uses one ambiguous word to create the impression that every prospective patient receives direct scrutiny from its highest-ranking physician. That impression reassures frightened families, strengthens confidence in the company’s admissions process and makes Alsana appear more medically rigorous than the available evidence supports.

The scale of the representation makes it even more doubtful. Alsana does not disclose its annual admission volume, but even modest assumptions reveal the physician time required for genuine individual reviews. At 750 admissions, a twenty (20) minute review would require approximately 250 hours each year; a thirty (30) minute review would require 375 hours. At 1,000 admissions, the commitment would rise to between approximately 333 and 500 hours annually.

Those figures exclude time spent obtaining missing records, requesting repeat testing, consulting with clinicians, documenting conclusions and performing Dr. Joglekar’s other duties as Chief Medical Officer. They must also be reconciled with his reported Monday through Friday internal medicine practice in which he represents to the Virginia Medical Board he devotes 100% of his time.

It is physically possible for a physician to open hundreds of electronic files. That does not mean he personally performs a substantive medical analysis of every patient, nor does it establish that he possesses the specialized experience necessary to make those reviews reliable. The more plausible inference is that Alsana’s admissions and nursing personnel perform the underlying work, with selected cases referred for some form of physician approval.

Alsana then converts that internal process into a sweeping public assurance that Dr. Joglekar reviews every prospective patient. In doing so, the company borrows the authority of his title while leaving the substance of his involvement carefully undefined.

Medical Authority Manufactured to Drive Admissions

Alsana took an internal medicine physician with no publicly documented eating disorder background and transformed him into a “leader in the eating recovery industry.” It then used his title to create the impression that every prospective patient receives individualized scrutiny from an experienced eating disorder medical authority.

The arrangement inverts the clinical hierarchy. Alsana’s frontline contract physicians and psychiatrists provide the actual patient care, (even if only virtually) and many possess direct eating disorder experience that is absent from Dr. Joglekar’s public professional record. Nevertheless, Alsana placed him at the apex of its medical structure without identifying the training, clinical history or specialized qualifications that would justify elevating his judgment above theirs. Clinicians with demonstrated experience therefore operate beneath a Chief Medical Officer whose claimed authority in the field can be traced only to Alsana’s promotional biography.

This is not merely inflated executive marketing. Alsana uses an unsubstantiated claim of specialized medical authority to reassure families deciding where to place medically compromised loved ones. By portraying Dr. Joglekar as an eating disorder leader and implying that he personally scrutinizes every admission, the company creates the appearance of a medical safeguard that the available evidence does not establish.

Physician authority has commercial value. It inspires trust, reduces fear and helps convert frightened families into admissions. Alsana wrapped that authority around a physician whose documented career is in internal medicine and whose supposed eating disorder leadership cannot be independently traced.

The white coat is real, but the specialized authority Alsana constructed around it is manufactured. And that manufactured authority is being used to sell treatment to families confronting a potentially fatal illness.

Alsana did not arrive in Birmingham as an innocent treatment provider suddenly confronted by an unpredictable act. It arrived carrying a corporate history of lax oversight, inadequate supervision, disputed treatment practices, warnings from former executives and unresolved patient safety failures at its facilities in Missouri. By the time a patient was sexually assaulted at its Birmingham residential program on July 26, 2025, Alsana had already been told, repeatedly and from multiple directions, what happens when growth, census and operational convenience overtake clinical judgment.

The assault was not the beginning of the story. It was the consequence.

Alsana may attempt to deflect and allege the attack was the unforeseen misconduct of one patient. However, evidence indicates that Alsana employees knew the offending patient had engaged in prior acts of public masturbation, sexually intrusive conduct, physical boundary violations and an escalating fixation on other vulnerable patients. Another former patient reported that the same individual sexually assaulted her and that management failed to act despite numerous prior reports. The eventual victim then warned staff directly, asked to be separated from the patient and explained that something was seriously wrong. Alsana left them together. After the sexual assault, the offending patient reportedly still remained in the program for a short period of time. Despite repeated warnings.

Reports indicate the offending patient was a private pay patient. Whether financial considerations influenced that decision is a question regulators and discovery will answer.

That sequence is the center of ongoing issues involving Alsana. Alsana sold safety, received warnings, yet failed to comply with its own safeguards and retained a patient whose conduct it was either unable or unwilling to manage. Once those facts are placed inside the company’s history, the July 2025 assault stops looking like an aberration.

Instead, it is the predictable result of the corporate system Alsana created.

The False Assurance of Safety

Residential eating disorder treatment is not housing with therapy added. Patients enter because they require an environment more structured and protective than the one they are leaving. The provider controls admissions, staffing, supervision, medical oversight, patient separation, behavioral intervention and discharge. Families entrust vulnerable loved ones because the company represents that it possesses the judgment and resources necessary to keep their loved ones safe.

Alsana continues to make precisely that representation. Its website promises a “safe, supportive space” and describes its residential program as providing structured care and support twenty-four hours a day, seven days a week. It created a marketing campaign emphasizing “Everyone deserves flowers.” The contrast is striking. While the company promoted “Everyone deserves flowers,” the allegations concerning staffing shortages, inadequate supervision, delayed intervention, and failures to protect vulnerable patients are especially troubling.

The Birmingham evidence indicates that when protection was actually required, another patient had to leave the victim during the assault and search for the only direct care employee available.

Alsana’s own staffing ratio was allegedly one direct care employee for every six patients. Seven patients were present that evening, including a patient whose known conduct demanded greater observation rather than the bare minimum. The same staffing deficiency allegedly appeared during a later physical altercation, when the sole direct care employee again had to leave the scene to obtain assistance. That repetition suggests an operating practice, not a solitary scheduling mistake.

This is where the marketing representation becomes deceptive.

Alsana advertised a controlled residential environment while staffing below its own ratio and retaining a patient whose behavior exceeded the facility’s ability to supervise. The company did not merely fail to prevent every conceivable act of misconduct. It failed to provide the protection it had promised after the specific danger was already known.

And yet, warning signs were present.

The Birmingham facility did not operate outside Alsana’s institutional history. Alsana was intertwined with Castlewood Treatment Center, whose Missouri operations generated years of controversy involving treatment practices, patient safety, supervision and institutional response. In 2022, admissions were halted at the St. Louis programs after allegations of inappropriate conduct involving direct care employees and a patient became public. This was only a few months after Alsana’s Birmingham operations opened.

In June 2022, Alsana’s former leaders also identified the corporate force driving these failures. Former CEO Jennifer Steiner testified under oath that she became concerned about Alsana’s decision to maximize growth and revenue and was then terminated and sued after refusing to support board decisions she believed would jeopardize patient care. Her exact words were: “Specifically, I became concerned with the direction of the company and what I considered to be Alsana’s decision to maximize growth and revenue above all else. When I refused to go along with certain decisions of Alsana’s Board, including decisions that I believed would jeopardize patient care, I was terminated.” 

Former Chief Clinical Officer Nicole Siegfried described growth and revenue being prioritized to the detriment of patient care, training, staff retention and culture. Other senior clinical leaders gave similar accounts.

Alsana’s former highest-ranking officers supplied more than reputational discomfort. They gave notice that weak supervision, boundary violations and an opaque response to patient complaints could cause serious harm. The Birmingham allegations involve those same categories: known inappropriate conduct, inadequate staffing, delayed intervention, fragmented authority and institutional secrecy after the event.

Alsana’s lack of transparency on its operation’s many failings extend to its very ownership.

Who owns this place?

In late 2016, The Riverside Company acquired Alsana. Press releases and social media announcements were plentiful.

These facts make it all the more perplexing when in August 2025, The Riverside Company divested itself of Alsana. There was no announcement. There were no press releases. None could be found. No buyer is identified. Alsana, whatever it is at this point, likewise failed to publicly disclose whether the transfer was an ordinary sale, a recapitalization, a lender-controlled transaction or a management acquisition.

New entities subsequently appeared. Alsana Parent Holdings, LLC, Alsana Holdings, LLC, Alsana Management, LLC, Alsana East LLC, Alsana West NorCal LLC and Alsana West – SoCal LLC. Most if not all of these entities were organized in Delaware and registered in the State of California.

However, what is curious is that none of these entities are listed with the Alabama Secretary of State and as such, are not authorized to conduct business in that state. What is also curious is that none of these entities are registered with the Alabama Department of Mental Health as a certified provider or are listed by the Alabama Department of Public Health Bureau of Health Provider Standards as a licensed facility operator.

The National Plan and Provider Enumeration System (“NPPES”) is a database managed by the Centers for Medicare & Medicaid Services (CMS) that assigns unique 10-digit National Provider Identifiers (NPIs) to healthcare providers and organizations in the United States. NPI records list Alsana Parent Holdings LLC as the parent organization for newly enumerated Alsana provider entities, including Alsana East LLC at the Birmingham address.

So, Alsana and whoever its owner and overlord is, publicly represented itself in a federal provider registry as connected to an Alabama psychiatric residential treatment facility and mental health clinic at 5101 Cyrus Circle in Birmingham. But, the Alabama Secretary of State, ADMH, and ADPH do not list them as authorized entities. Which to families seeking care and treatment should be very concerning.

Patients and regulators are entitled to know who oversee operations, appoints the board, controls staffing budgets, selects medical leadership and assumes responsibility for the liabilities inherited from Missouri and Birmingham.

Rather than provide any answers, Alsana expanded its virtual treatment program to include up to 40 states in early 2026. This should not be surprising since at least some of Alsana’s independent contractor medical doctors appeared only virtually in Birmingham. You entrust your loved one to a brick-and-mortar residential treatment center. And the medical doctor overseeing your child’s care is a mere face on a laptop monitor.  

On the other hand, Alsana did launch its “Soul Hearted” rebranding campaign, promising that patients and the eating disorder field “deserve flowers.” The campaign presented a “new beginning” without acknowledging the company’s history, former executive warnings, unresolved ownership questions or allegations of patient harm.

The flowers are not harmless silliness. They are reputation laundering through emotional imagery. Alsana is asking the public to experience the company as compassionate while withholding information necessary to judge whether it is safe.

Alsana Was Offered an Honorable Way Out

Before administrative complaints or litigation, Alsana and the responsible parties received an extensive pre-suit brochure. It explained the prior warnings, the assault, the alleged cover-up, the staffing failures, Missouri history, former executive testimony, ownership questions and physician licensure concerns.

The proposal gave Alsana a professional way to resolve the victim’s private claims. It did not demand the concealment of patient safety information, withdrawal of regulatory reports or silence concerning matters within the jurisdiction of government agencies. The victim expressly preserved her right to communicate truthfully with licensing and patient safety authorities.

Alsana could have compensated the victim, confronted the evidence and begun demonstrating that accountability would finally replace concealment. Attorneys appointed through its directors and officers insurance coverage initially engaged in discussions. They then stopped responding substantively.

Silence was their choice. But silence does not erase the evidence or prevent the next stage.

First the Regulators. Then the Courthouse.

Administrative complaints will now be filed with the Alabama Department of Mental Health, the Alabama Board of Medical Examiners and any other licensing authorities possessing jurisdiction. Those complaints will address staffing, incident reporting, patient retention, ownership disclosures, physician credentialing, telemedicine practices and whether present patients remain exposed to the same institutional failures.

Civil litigation will follow the administrative complaints. Discovery will obtain the prior reports, staffing records, private pay revenue, internal communications, Missouri investigations, Riverside’s exit, the new holding companies and every decision that left a known sexual safety risk in the residential population.

Alsana was warned in Missouri. Its former executives warned the board. Patients warned the Birmingham staff. The victim asked for protection. After the assault, Alsana was offered an honorable opportunity to resolve her private claims without buying silence from the public or the regulators.

Instead, Alsana chose concealment, flowers and silence.

Not a statistic.

But people.

101,132 is the number of people who will have died from eating disorders between October 30, 2016, at 11:31 p.m. and October 30, 2026, at 11:31 p.m.

101,132 people.

Enough to overflow Darrell K Royal–Texas Memorial Stadium at the University of Texas.

Enough to fill Bryant-Denny Stadium at the University of Alabama and still leave people outside the gates.

Enough to come within a few hundred seats of filling Neyland Stadium at the University of Tennessee.

Or leave those stadiums empty, devoid of all life. Devoid of all souls.

101,132 is roughly the population of Boca Raton, Florida. It is the size of New Bedford, Massachusetts. It is Albany, New York. It is Wichita Falls, Texas.

An entire city.

Families. Bedrooms. Birthday candles. School pictures. Text messages that were never answered. Mothers who still listen for footsteps. Fathers who still calculate time by the minute their child died.

My daughter Morgan died from anorexia on October 30, 2016 at 11:31 o’clock p.m.

Ten years later, using the eating disorder mortality rate this field itself has reported, more than 101,000 people will have died in the ten years after that dark night.

During that decade, the eating disorder ecosystem celebrated itself. It held conferences. Issued statements. Sold treatment. Protected brands. Promoted awareness. Fought over ideology and turf. Guarded reputations. Raised paltry sums of money. Published slogans.

And the deaths kept coming.

One every 52 minutes.

Not because no one knew.

Not because the danger was hidden.

Not because families failed to love hard enough.

But because an entire system learned how to live within the crisis without solving it.

That is the indictment.

Equip’s High Acuity Email and the Fraud Warnings Inside the Company

In eating disorder care, “highest acuity” is not a casual descriptor. It is a clinical alarm. It signals patients whose medical stability is fragile, whose psychiatric risk is elevated, and whose margin for error is dangerously thin. A margin for error so thin that the wrong setting can become catastrophic.

Despite the fact that Equip knew, or should have known what that phrase means, it did not treat this phrase as a warning. Instead Equip turned it into a sales pitch.

In its solicitation email sent to referral sources, Equip asked providers to transition their “highest acuity” eating disorder patients to Equip’s “acute, virtual care.” The same solicitation positioned Equip against residential treatment, partial hospitalization, and intensive outpatient care.

That was not ordinary marketing. It was a clinical capacity representation.

Equip was telling referral sources that its virtual model could handle some of the sickest eating disorder patients. Not routine outpatient cases. Not mildly symptomatic patients. The highest acuity patients.

That claim must now be judged against what Equip already knew.

Equip’s public materials describe a fully virtual program that treats medically stable patients across a wide spectrum of acuity levels, including patients who might otherwise seek residential treatment, PHP, IOP, or outpatient care. Equip also defines high acuity to include patients frequently engaged in eating disorder behaviors, moderately to severely malnourished, and at elevated risk of medical or psychiatric instability. It claims to have treated 6000 “high acuity” patients.

Those facts do not point toward casual outpatient care. They point toward the very questions Equip’s marketing appears to soften. Does the patient need PHP? Residential treatment? Inpatient stabilization? Supervised meals? Direct medical monitoring? Psychiatric hospitalization? A setting where someone can see what the illness is doing when the patient and family cannot?

Equip’s model narrows the issue to a different question … can the patient be called medically stable enough for virtual care?

That is the pressure point. Equip kept the gravity of high acuity but changed the practical effect of the phrase. Instead of warning providers to slow down and scrutinize level of care, “high acuity” became proof that Equip could handle serious cases. It became a growth category.

And yet, former employee reviews make that claim far more serious. Make no mistake, I treat most disgruntled employees’ claims with a ton of salt. Complaints about working conditions, DEI being deemphasized, officers’ vacations being mischaracterized can readily be dismissed. But consistent, substantive complaints regarding the patient population and quality of care are a different matter.

One former employee alleged that Equip admitted clients who did not belong in virtual care, made it impossible to discharge clients who needed a higher level of care, stacked therapist caseloads, fired employees who questioned the business model, and asked providers to practice outside states where they were licensed.

Another former employee alleged little to no criteria for medical clearance before admission, patients being admitted without signed consent forms, difficulty discharging patients who required higher care, and clinicians expected to practice outside their scope without adequate training or support.

Another review alleged that medically unstable patients were not discharged and that providers were required to continue seeing patients who were inappropriate for virtual care while the company moved toward volume driven metrics over clinical quality.

Other comments alleged Equip accepted patients who met criteria for Denver Acute and patients with heart rates in the 30s.

Several former employees claim that providers were pressured to practice in states where they were not licensed and asked to misrepresent information on licensing applications. They further claim that inaccurate information has been provided regarding licensing and credentialing requirements. These are not administrative oversights. They are legal and ethical violations that put providers’ licenses on the line.

Still other employees claimed that medically unstable patients were not discharged and employees were required to continue to see patients who were inappropriate for virtual care. They claim supervisory support was minimal, and the organizational focus shifted toward volume driven metrics over clinical quality. Alleged high staff turnover in multidisciplinary departments further impacted the stability of patient care.

These allegations are not background noise. They go to the center of Equip’s business model … who was admitted, who was kept, who was cleared, who was licensed, who was overloaded, and whether Equip’s public promise matched its clinical reality.

Knowledge is the crucial factor.

If leadership knew clinicians were warning about inappropriate admissions, blocked discharges, weak medical clearance, licensure problems, unsafe caseloads, and patients too sick for virtual care, then Equip’s highest acuity email is no longer simply bold marketing. It becomes a knowing misrepresentation made after due warning. Former employees claim that leadership did know.

That is the clear line between mistake and misrepresentation.

A company can be wrong. A company can overpromise. A company can launch a model that later proves unsafe. But when internal warnings exist before the public pitch is even made, the inquiry changes. The question becomes whether executives, directors, medical leaders, and compliance personnel allowed referral sources, families, insurers, and Medicaid programs to rely on a version of Equip that they knew was false.

And that is where fraud could enter the picture.

Fraud is not just a bad claim. It is a bad claim made with knowledge, reckless disregard, or deliberate blindness. In federal health care programs, that distinction can carry enormous consequences. Equip claims to accept Medicaid in four states. That is a complicating factor.

The Department of Justice states that any person who knowingly submits or causes the submission of false claims to the government can be liable for three times the government’s damages plus inflation linked penalties. The False Claims Act also reaches false records material to false claims, improper avoidance of obligations to repay the government, and conspiracy.

The Office of Inspector General for the U.S. Department of Health and Human Services (“HHS OIG”) tells physicians that it is illegal to submit Medicare or Medicaid claims they know or should know are false or fraudulent. OIG also says civil False Claims Act liability can include up to three times the program loss plus penalties per claim, that no specific intent to defraud is required, and that “knowing” includes actual knowledge, deliberate ignorance, and reckless disregard.

That means Medicaid exposure would not necessarily stop at Equip as a company.

If Medicaid paid for claims based on false or misleading representations about medical necessity, licensure, medical clearance, clinical capacity, provider supervision, or appropriate level of care, then the people who caused, approved, continued, or concealed those representations could face scrutiny. That includes high ranking officers. It includes medical directors. It includes physicians who cleared, supervised, billed, or continued patients inside a model they knew was not safe or properly supported. And persons on the board of directors.

Civil liability is only part of the risk. HHS OIG identifies the False Claims Act, Anti-Kickback Statute, Stark law, exclusion authorities, and civil monetary penalties law as major federal fraud and abuse laws affecting physicians. OIG warns that violations can result in criminal penalties, civil fines, exclusion from federal health care programs, or loss of a medical license. OIG also states that criminal penalties for submitting false claims include imprisonment and criminal fines, and that physicians have gone to prison for false health care claims.

Equip’s email cannot be dismissed as a dispute over branding.

By the time Equip asked referral sources for their “highest acuity” eating disorder patients, former employees had raised the very concerns that would make that solicitation dangerous … patients too sick for virtual care, blocked discharges to higher levels of care, weak medical clearance, unsafe caseloads, licensing problems, and a widening gap between what Equip marketed and what its clinicians could safely deliver.

That sequence changes everything.

Equip did not merely claim it could treat eating disorders virtually. It claimed clinical capacity for high acuity patients while sitting on internal warnings that some patients were being admitted, retained, or managed in ways the model could not safely support.

Families were not being asked to buy software. They were being asked to trust a clinical promise. Providers were not sending names into a neutral intake portal. They were relying on Equip’s representation that its virtual model could safely absorb serious eating disorder cases. Medicaid programs and insurers were not paying for slogans. They were paying for care that had to be medically necessary, properly supervised, lawfully provided, and appropriate for the patient’s level of risk.

That is where the alleged misconduct becomes more than marketing.

If Medicaid paid claims while Equip knew, or recklessly ignored the reality that patients were being treated in the wrong setting, cleared under inadequate medical standards, served by providers with licensing problems, or kept in virtual care despite the need for a higher level of care, the inquiry should not stop with the company’s marketing department. It should reach the officers who approved the growth strategy, the executives who received the complaints, the medical leaders who signed off on clinical practices, the compliance personnel who knew the risks, the physicians who cleared or continued patients, and the board members who had a duty to know what was happening inside the company they governed.

That is the fraud question.

Not whether Equip can point to families it helped.

Not whether virtual care can sometimes work.

Not whether the word “high acuity” can be softened by adding “medically stable.”

The question is whether Equip continued selling high acuity virtual care after it knew, or should have known, that its own clinicians were warning the model was taking patients it could not safely hold.

If leadership did not know, they epically failed. If leadership did know, the email was not an accident. It was a solicitation made after warnings. After knowledge. After acquiescence.

And once warning exists, the next referral, the next admission, the next Medicaid claim, and the next family persuaded to trust virtual care all carry a different meaning.

“Highest acuity” should have stopped the process.

Instead, Equip used it to open the funnel.

Equip’s High-Acuity Email Came Between Corporate Layoffs

First, Equip restructured and laid off employees. Then it asked medical and mental health providers to send the sickest eating disorder patients into “acute, virtual care.” Then more corporate employees were cut.

That is the sequence. It is also the problem.

Equip’s provider solicitation did not advertise a limited outpatient service for carefully screened medically stable patients. It asked medical and mental health professionals to “transition your highest acuity ED patients into acute, virtual care.” The same communication positioned Equip against residential treatment, partial hospitalization, and intensive outpatient care.

That was not casual marketing language. It was a clinical capacity claim made to referral sources.

Three months before the solicitation, Equip underwent corporate restructuring that included layoffs. Companies do not restructure and cut staff because everything is calm. They do it because money, operations, strategy, or survival has forced a change.

Then on or about June 25, 2026, a separate source reported that Equip laid off more of its corporate staff. According to that source, the cuts appeared to include persons who had been employed from the first year with the pattern falling on longer term employees tied to the company’s original vision and likely higher paid.

The email now reads differently. It cannot be regarded as a stray exaggeration from a stable company. It was a high acuity referral solicitation sent between two corporate reduction events.

Equip’s investor board cannot plausibly stand outside that sequence. It is implicated within those decisions. As such, the make-up of the board of directors must be examined. Once this is done, a clearer picture starts to come to light.

Equip lists five people on its board of directors. Each person is affiliated with a venture capital company that invested in Equip. General Catalyst. F-Prime Capital. Adams Street Partners. Optum Ventures. The Chernin Group.

There are no medical doctors, mental health experts, nutritionists, or therapists. No one with any appreciable eating disorder experience. Just five persons all of whom are employed by Equip’s investors.

Investor directors exist to know the company’s financial condition. Burn rate, runway, payer growth, staffing costs, restructuring, layoffs, referral strategy, and Medicaid expansion are board level facts in any venture backed healthcare company. A board member who knew about the restructuring and allowed the solicitation to proceed cannot later pretend the email existed apart from the company’s financial condition. A board member who did not know has a different problem: ignorance of the very facts an investor director exists to monitor.

The email solicitation’s defect lies in what it communicated and what it withheld. Medical and mental health providers were told to transition the highest acuity eating disorder patients into Equip’s acute virtual care. That language carries an implied representation that Equip had the staffing, screening, medical oversight, clinical infrastructure, family support systems, emergency escalation pathways, and operational stability to receive those patients.

The email solicitation omitted the restructuring, the prior layoffs, any pending or foreseeable reduction, and any explanation of whether cost pressure had reached clinical operations, admissions standards, medical monitoring, escalation systems, quality controls, or patient support.

That omission changes the legal character of the email.

A medical or mental health provider reading the solicitation was not merely evaluating another telehealth option. The provider was being asked to rely on Equip’s implied representation that the company could safely absorb the population it was soliciting. Financial pressure, staff reductions, removal of longer-term employees, and board knowledge bear directly on that representation.

High acuity eating disorder patients are not ordinary outpatient consumers. Some are medically fragile. Others are psychiatrically unstable, nutritionally compromised, behaviorally unsafe, or dependent on structure a remote platform cannot provide. Medical hospitalization, psychiatric hospitalization, residential treatment, PHP, and IOP exist because certain patients need containment, observation, stabilization, and immediate escalation.

Equip’s email did not lead with medical stability, exclusion criteria, adverse event data, hospitalization rates, step up rates, or limitations on remote care. It led with the highest acuity patients.

An extensive FTC complaint, with supporting documentary evidence has already been filed against Equip. This FTC complaint should be read as more than an advertising substantiation complaint. It is a material omission and misrepresentation complaint.

In addition, complaints are being prepared and will be submitted in the four states where Equip accepts Medicaid. These complaints will include the latest information about employee layoffs.

The Medicaid issue is particularly troubling. Equip publicly represents that millions of Medicaid members can access its services. Public payers do not occupy the same position as private consumers scrolling through marketing copy. State Medicaid programs and Medicaid managed care organizations rely on provider representations about capacity, acuity, medical necessity, safety, network adequacy, and payment eligibility.

A Medicaid plan is entitled to know whether a virtual eating disorder company soliciting high acuity referrals had recently restructured, cut staff, and entered another round of corporate layoffs. A state agency is entitled to examine whether public beneficiaries were steered toward remote care because the placement was clinically appropriate or because a venture backed provider needed volume. Families are entitled to know whether a company asking for high acuity patients had disclosed the operational facts necessary to evaluate that invitation.

The serious legal problems of Equip and Equip’s board of directors do not stop with that reality.

The legal danger is not that Equip sent one irresponsible, possibly fraudulent email. The danger is that the email may have been one step in a revenue pathway: provider solicitation, patient intake, insurance authorization, Medicaid managed-care approval, treatment billing, and outcome claims. If the same high-acuity message traveled through that pathway while internal documents showed financial pressure and reduced staff, investigators will not treat the email as a mistake. They will treat it as evidence.

That is why healthcare fraud, false statements, wire fraud, and even racketeering belong in the conversation. Each theory turns on proof: what Equip knew, what it concealed, how often the claim was repeated, who approved it, whether payers relied on it, and whether money was obtained through the resulting referrals or claims.

Racketeering belongs on the table for the same reason.

One bad email is not RICO. A continuing revenue scheme built on electronic misrepresentations can be.

The RICO question is whether the solicitation was part of a broader pattern of revenue generation through high acuity misrepresentation. RICO is not triggered by outrage. It is triggered by pattern. The question is whether Equip’s high-acuity pitch appeared once, or whether the same representation moved repeatedly through referral emails, intake scripts, payer authorizations, Medicaid communications, patient enrollment materials, and claims for payment.

Those questions belong in subpoenas, civil investigative demands, Medicaid program integrity requests, and litigation discovery.

The board’s role cannot be minimized. Investor directors had the strongest motivation to track financial condition and the clearest access to the company’s internal truth. Restructuring before the solicitation was not hidden clinical minutia. Layoffs after the solicitation were not random background noise. Together, they create a timeline that places board knowledge, operational pressure, and high acuity marketing in the same frame.

Equip may deny financial distress. It may say the restructuring was ordinary. The company may insist patient care was unaffected, that “highest acuity” excluded medically unstable patients, or that “acute virtual care” referred only to a screened population suitable for home-based treatment. Those defenses require documents, not adjectives.

Any serious investigation will begin with the approval chain: who drafted the solicitation, who approved the acuity language, which executives saw it, whether legal or clinical leadership reviewed it, and whether the board received performance reports after it went out. The next production should reach board decks, restructuring documents, layoff plans, runway projections, payer-mix reports, Medicaid expansion materials, referral targets, staffing data, escalation protocols, adverse-event reports, hospitalization rates, step-up rates, dropout rates, and outcomes by acuity.

The same production inevitably will show whether legal, compliance, or clinical leadership reviewed the solicitation. Regulators will ask whether anyone compared the email to the company’s actual staffing and financial condition. Payers should demand proof that Equip’s claims about acuity, capacity, and outcomes were accurate when made. State Medicaid agencies should examine whether public beneficiaries were enrolled through a referral pathway built on incomplete clinical and operational misrepresentations.

This is no longer a narrow fight over telehealth language.

Virtual treatment can help some eating disorder patients. In person family-based care has evidence. Remote access can reduce geographic barriers. Medicaid coverage can expand treatment options for families who have been shut out of care. None of that gives a venture backed company permission to solicit high acuity patients while withholding the financial and operational facts needed to evaluate the solicitation.

The public record now shows a sequence that regulators will not be able to ignore. Restructuring and layoffs, high acuity solicitation, more layoffs. Equip’s board exclusively consisted of investor affiliated directors. The company’s model reaches Medicaid beneficiaries. The email asked providers to transition the highest acuity eating disorder patients into acute virtual care.

Equip can call the email marketing. Regulators should call it damning evidence.

A company that restructures, cuts staff, solicits the sickest eating disorder patients, and then cuts more staff has created a record. An investor board cannot govern that company for growth and then deny knowledge when the growth message becomes dangerous.

The email opened the door. The layoffs supplied the context. The board owns the rest.

The Morgan Dunn Eating Disorder Education Act

For decades, families and clinicians have known that physicians can miss signs and symptoms of eating disorders until the damage is severe.

The signs are not confined to one specialty. Eating disorders may surface through rapid weight loss, growth disruption, dizziness, gastrointestinal complaints, menstrual changes, electrolyte abnormalities, compulsive exercise, purging, diabetes manipulation, depression, anxiety, self-harm, or unexplained medical decline. Body mass index can appear acceptable while the body is already in danger. A patient may look articulate, functional, and medically stable until the illness becomes a crisis.

That is why medical education is crucial.

Eating disorders are not matters of vanity, lifestyle, discipline, or willpower. They are serious psychiatric and medical illnesses that can cause permanent injury and death. Yet there are no enacted federal or state laws requiring medical schools to provide eating disorder education as part of the required medical degree curriculum, much less a law specifying hours, core content, competency assessment, annual certification, and corrective action.

That absence should shock people outside the eating disorder world. It should shame people inside it.

The field has awareness. Conferences have named the problem, families have testified to it, continuing education programs have addressed pieces of it, and public campaigns have repeated the importance of early detection until the language became familiar enough to lose force. None of that requires a medical school to change its curriculum. A webinar does not create a public record of compliance. A slogan about early intervention does not ensure that future physicians learn how to recognize medical instability, refeeding risk, weight suppression, diagnostic bias, or the danger of relying on body mass index alone.

The question is no longer whether the eating disorder community understands the problem. It plainly does. The question is why that knowledge has not been converted into state-level legislation requiring medical schools to teach future physicians before patients are harmed.

Part of the answer lies in the direction of the field itself. As private equity and large treatment platforms gained influence, advocacy increasingly moved downstream toward reimbursement, coverage, parity, treatment access, residential care, and payment for services after a diagnosis had already been made. Those issues are real. Families need coverage. Patients need care. But reimbursement policy does not protect the patient whose physician was never taught how to recognize the illness in the first place.

A system focused on paying for treatment after identification leaves the first failure intact.

That is the gap the Morgan Dunn Eating Disorders Education Act is designed to close.

During the next Texas legislative session starting in January 2027, I intend to have filed the Morgan Dunn Eating Disorders Education Act. This bill requires medical degree programs in Texas to provide core instruction on eating disorders before graduation. It is not an awareness resolution, a symbolic proclamation, or a request that schools consider the subject if time allows. It establishes a minimum legal requirement: at least eight hours of instruction and at least one case-based assessment showing that a student can recognize, medically assess, and make an appropriate referral or management plan for a patient with a suspected eating disorder.

The requirement is modest. The need is not.

The instruction would include diagnostic warning signs, medical complications, starvation, malnutrition, purging, laxative misuse, compulsive exercise, binge eating, refeeding risk, screening, physical examination, laboratory evaluation, medical stabilization, urgent referral, higher levels of care, psychiatric comorbidity, weight stigma, diagnostic bias, and continuity of care. The bill also addresses patients too often missed by stereotype, including children, males, pregnant patients, patients with diabetes, patients in larger bodies, patients with disabilities, and patients from diverse racial, ethnic, and socioeconomic backgrounds.

The bill is also drafted to answer predictable objections.

1.         Medical schools will say their curriculum is crowded.

The bill preserves flexibility. Eating disorder education can be placed inside psychiatry, pediatrics, internal medicine, family medicine, emergency medicine, OB/GYN, adolescent medicine, endocrinology, nutrition, clinical skills, behavioral health, clerkships, modules, case-based learning, or an integrated course. No school is forced to create a freestanding class unless it chooses to do so.

2.         Medical educators may say legislators should not dictate curriculum.

The bill does not dictate pedagogy. Faculty governance remains intact. Schools control placement, sequencing, method, assessment, and faculty assignment. The Legislature sets the public safety floor.

3.         Institutions may worry about liability.

The bill expressly avoids creating a private cause of action, a new professional standard of care, or a new evidentiary rule. It is an education mandate, not a litigation trap.

4.         Administrators may resist reporting.

The requirement is limited. Schools must certify compliance, identify where the instruction appears, state the approximate number of instructional hours, and describe how completion or competency is assessed. A school that falls short receives notice and an opportunity to correct the problem.

5.         Legislators may presume the bill creates a new state expense.

That concern misunderstands the design. The bill does not create a new agency, hire inspectors, fund a grant program, purchase a proprietary curriculum, build a treatment network, or create a state-funded training vendor. Compliance would occur inside medical schools that already maintain required curricula, student assessment systems, faculty governance, accreditation processes, and reporting infrastructure. The state’s role is basic accountability: receive certifications, identify noncompliance, and require correction.

Taken together, those answers make the bill difficult to caricature. It does not regulate treatment centers, expand Medicaid, create a lawsuit, or attempt to repair the entire eating disorder system through one statute. The demand is narrower and harder to evade. Texas medical schools may decide how to teach the material, but they should not be permitted to graduate future physicians without baseline training in illnesses they are certain to encounter.

Sadly, the larger obstacle may come from the eating disorder ecosystem itself. That indictment belongs in the open.

For years, organizations with platforms, donors, clinicians, researchers, treatment providers, and lobbyists could have drafted model legislation and taken it state-by-state. Instead, the public agenda too often remained in the safer territory of awareness, resources, messaging, and reimbursement. The result is a field that can describe missed diagnosis in detail while leaving medical schools under no legal obligation to teach future physicians how to prevent it.

This is not a lack of compassion. It is a failure of legislative will.

The Morgan Dunn Eating Disorders Education Act changes the question. Should a medical student be allowed to graduate in Texas without required instruction on eating disorder warning signs, medical complications, refeeding risk, medical instability, appropriate referral, and the dangers of relying on body mass index alone?

If the answer is no, the case for the bill follows.

Texas is the right place to start. The state has already recognized through recent health and nutrition legislation that medical education is a legitimate site for prevention. Eating disorder education belongs in that same frame. Physicians should be able to counsel patients about nutrition, diabetes, metabolic health, exercise, cardiovascular risk, and obesity. But they must also know when weight loss is not health, when restriction is not discipline, when exercise is not recovery, when body size conceals danger, and when a nutrition message can worsen a psychiatric illness.

There is no contradiction between prevention and eating disorder education. The contradiction lies in teaching future physicians about nutrition while leaving them underprepared to recognize starvation, purging, weight suppression, refeeding risk, and medical instability.

Eight hours will not fix the eating disorder treatment system. It will not solve insurance denials, provider shortages, hospital failures, residential treatment problems, or the divide between psychiatric and medical care.

But it can change the first medical encounter.

A physician who has been taught what to look for is more likely to recognize danger, ask the right questions, assess medical risk, and refer before the window for intervention closes. That is the purpose of the Morgan Dunn Eating Disorders Education Act. It asks Texas to not tolerate one indefensible failure: future physicians graduating without required training in illnesses that can permanently injure or kill patients when missed.

That should not be controversial. It should already be law.

[For a copy of the proposed bill, contact me. I welcome all comments and ways we can make the bill even stronger.]

Equip’s Transition

Equip Health recently sent medical and mental health treatment providers this referral solicitation email.

Notice the subject line which should be read exactly as written:

Subject: “Transition your highest-acuity ED patients—into acute, virtual care.”

That sentence is not casual marketing. It is the claim. It is also worthy of regulatory agency investigation.

Before the reader reaches the body of the email, Equip has combined three clinically loaded concepts: highest acuity, acute care, and virtual treatment. The result is not an access message. It is not a modest statement that medically stable patients may receive step down support at home. It is a solicitation asking providers to move the sickest eating disorder patients into a virtual program described as acute care.

Equip may attempt to walk back its representation and offer a narrower interpretation. It may say the representation meant patients who had already achieved medical stability and were appropriate for step down treatment. But that defense relies upon words the email did not use.

Equip did not limit the claim to patients who had been medically stabilized, medically cleared, or found no longer to need inpatient or residential care. It did not confine the solicitation to medically stable patients appropriate for step down treatment. The words it chose were broader, more aggressive, and more clinically consequential.

“Transition your highest-acuity ED patients into acute, virtual care.”

That is a placement claim.

In eating disorder treatment, highest acuity is not a branding term. It points toward patients with serious medical, psychiatric, nutritional, behavioral, or environmental risk. Depending on the case, the phrase may involve bradycardia, hypotension, syncope, electrolyte disturbance, severe malnutrition, refeeding risk, acute suicidality, self-harm, uncontrolled purging, compulsive exercise, laxative misuse, food refusal, failed lower levels of care, or a home setting unable to contain the illness.

Those are not convenience care problems. They are level of care problems.

Some require medical hospitalization. Others require psychiatric inpatient treatment. Some belong in residential care. Others may need PHP, IOP, or carefully monitored outpatient treatment after stabilization. The clinical issue is not whether virtual care can ever help. It plainly can. The issue is whether a fully virtual program should be marketed to referral sources as “acute” care for the “highest acuity” eating disorder patients.

Equip’s email says yes. The evidence does not justify that confidence.

The body of the email makes the subject line harder to dismiss. Equip tells providers that it is a “common misconception” that virtual eating disorder care is only for less complex patients seeking IOP or outpatient treatment. It says patients who are medically, psychologically, or socially complex, or recently hospitalized, can receive the structured support they need through Equip. It describes the company’s 100 percent virtual model as a direct alternative to residential treatment, PHP, and IOP. It claims more than 6,000 high acuity patients successfully treated in two years. It invokes medical safety, strict protocols, and the gold standard of family-based treatment.

Each phrase is material. Together, they create a net impression: Equip is not merely offering virtual outpatient care. It is positioning its model as a substitute for higher levels of care, including for patients described as high acuity or even highest acuity.

That is where the substantiation problem escalates.

FBT has evidence. Virtual FBT has a smaller and less mature evidence base. Equip’s proprietary virtual model is a separate proposition. A fully virtual model marketed as a direct alternative to residential treatment, PHP, and IOP is another proposition still.

In an attempt to gain legitimacy, Equip’s email collapses those categories.

Evidence for in person FBT cannot simply be transferred to virtual FBT. Evidence that virtual FBT may be feasible for selected medically stable patients cannot be stretched into proof that a virtual commercial platform is equivalent to higher levels of care. Company associated outcomes do not become independent validation because the model is built around a recognized therapy.

That is evidentiary laundering. A valid treatment principle is being used to support a broader commercial claim the public evidence has not established.

The existing virtual FBT literature appears to support a narrower statement: virtual FBT may be feasible, acceptable, and useful for selected patients, particularly medically stable adolescents and young adults with adequate family support and access to medical monitoring. That is meaningful. But it is not a finding of equivalence to in person FBT. It is not proof of non-inferiority. It is not evidence that residential care, PHP, or IOP can be replaced for patients who meet those levels of care.

No independent, third party, comparative trial has established that virtual FBT is as effective as in person FBT for adolescent anorexia nervosa. No independent objective trial appears to establish that Equip’s model is equivalent to standard in person FBT. No public independent evidence appears to show that Equip’s fully virtual program is clinically equivalent to residential treatment for patients who meet residential criteria.

Yet the email calls the model a direct alternative.

A direct alternative requires direct proof.

Residential treatment, PHP, and IOP are not interchangeable marketing categories. Each level exists because certain patients need more structure than ordinary outpatient care. At the upper end, care may require direct observation, medical stabilization, supervised meals, behavioral containment, psychiatric safety planning, or twenty-four-hour structure. Whether every program performs those functions well is a separate issue. The level of care exists because the functions are clinically necessary for some patients.

Equip’s model may provide real services: therapy, nutrition support, family coaching, medical coordination, remote meal support, protocols, and escalation. Those services can matter. They do not, by themselves, constitute acute care. They do not establish equivalence to residential treatment. They do not prove safe management of the highest acuity patients.

The distinction is not semantic. It is the patient safety line.

Equip’s own public materials reportedly recognize a limiting principle: the company describes its care as appropriate for medically stable patients and indicates that patients are medically cleared before enrollment. That qualifier is decisive. Medically stable step-down care is one proposition. Highest acuity acute virtual care is another.

The email blurs the difference.

“Medically complex” does not mean medically stable. “Recently hospitalized” does not mean ready for virtual care. “Would otherwise require residential treatment” does not mean safe to manage at home. “High acuity” is not an outcome. “Successfully treated” is not evidence unless the terms are defined and the failures are disclosed.

The claim that Equip has treated more than 6,000 high acuity patients in two years demands answers. What counted as high acuity? How was success defined? How many patients were screened but rejected? How many were excluded because they were medically unstable? How many lacked adequate caregiver support? How many dropped out? How many required hospitalizations during treatment? How many stepped up to residential, PHP, IOP, medical inpatient, or psychiatric inpatient care? How many relapsed after discharge? How many were lost to follow up? How many actually met independent residential criteria at the time of referral?

Without that denominator, “6,000 high acuity patients successfully treated” is a marketing plan, not scientific proof.

The phrase “grounded in medical safety” has the same defect. In a virtual model, medical safety depends on selection, exclusion, honest reporting, reliable caregivers, local medical access, timely vitals, timely labs, ECGs when indicated, and rapid escalation. Those dependencies may support appropriate virtual treatment for selected patients. They do not transform a remote program into an acute care setting.

Equip’s email made objective health claims in a commercial referral solicitation. The claims concerned acuity, medical safety, treatment success, and level of care substitution. They were directed to providers who influence where vulnerable patients receive care. If Equip cannot substantiate those claims with competent and reliable evidence specific to the representations made, the email is not aggressive education. It is deceptive health marketing. The same type of marketing the FTC has investigated with other providers in the past.

Commercial context reinforces the need for scrutiny. Equip is a venture backed virtual treatment company operating in a payer sensitive field where facility-based care is expensive and often contested. A virtual alternative to residential treatment is attractive to insurers. It is scalable. It may be cheaper to authorize. It can be framed as modern, accessible, and evidence based. None of that proves misconduct. It explains why broad claims about “highest acuity” and “acute virtual care” require exacting proof.

The public interest is greater because Equip is not operating only in the commercial insurance market. Equip states that more than seven million Medicaid members can access its services, that it accepts Medicaid plans in several states, and that it is working to expand across state Medicaid programs and managed care organizations. If a company markets a fully virtual model as acute care for high acuity eating disorder patients, or as a direct alternative to residential treatment, PHP, and IOP, the question is not limited to whether private families were persuaded by aggressive marketing. The question is whether Medicaid beneficiaries, Medicaid managed care plans, state Medicaid agencies, and public healthcare dollars may be relying on the same claims.

Medicaid participation requires a higher level of public scrutiny. Medicaid patients often have fewer covered alternatives, less access to specialized in person eating disorder treatment, and less practical ability to obtain independent review when a covered virtual option is presented as appropriate. If Equip means medically stable patients who have been screened and cleared for virtual treatment, it should say that with precision. If it means Medicaid patients who would otherwise meet criteria for residential, PHP, IOP, medical hospitalization, or psychiatric hospitalization, it should publish evidence strong enough to support that substitution.

Equip may criticize residential treatment. The residential sector has earned scrutiny. But the flaws of one system do not validate a commercial replacement. A company cannot attack higher levels of care as insufficiently proven, then market its own virtual model as a direct alternative without independent evidence commensurate with that claim.

The burden is simple.

If Equip means medically stable patients appropriate for step down care, it should say that. If Equip means highest acuity patients, it should produce the evidence. If Equip means a direct alternative to residential treatment, PHP, and IOP, it should publish the comparative data.

Produce the independent study showing virtual FBT is noninferior to in person FBT. Produce the independent study showing Equip’s proprietary model is equivalent to in person FBT. Produce the independent study showing a fully virtual model is a safe and effective direct alternative to residential treatment for patients who meet residential criteria. Publish the denominator. Publish exclusion criteria. Publish hospitalization rates. Publish step up rates. Publish dropout rates. Publish adverse events. Publish relapse data. Publish outcomes by diagnosis, acuity, medical risk, purging behavior, suicidality, weight status, prior hospitalization, and caregiver availability.

Until then, the email should be read for what it is: a commercial solicitation asking providers to transition the sickest eating disorder patients into a virtual model on claims Equip has not publicly proved.

Not proof.

Not science.

Not validated acute care.

Merely a sales document. And a sales document worthy of federal agency investigation at that.

Five Million Dollars is not a Victory. It is an Indictment.

The EDCoalition and some advocates are celebrating the June 12, 2026, announcement of the House Appropriations Committee’s advancement of $5 million for eating disorder prevention, screening, training, early detection, and related work. They posted, “We did it EDCoalition!”

In the narrow world of appropriations politics, some may call that a win. They believe that any federal recognition of eating disorders is better than silence. Others more appropriately call it, “dereliction of duty.”

But that is just one of the many problems. The baseline has been set so low that symbolic movement can be mistaken for serious action.

Five million dollars is not a serious federal commitment to eating disorder research. It is not close. Measured against the federal budget, comparable psychiatric and substance use conditions, the mortality rate of eating disorders, and twenty-five years of organized federal advocacy, the number is not a breakthrough. It is damning evidence of gross incompetence.

For 2026, the Congressional Budget Office projects total federal outlays at approximately $7.4 trillion. Against that number, $5 million for eating disorders represents about 0.0000676% of federal spending.

For greater perspective, for every $1 million the federal government spends, this eating disorder package represents roughly 68 cents.

That is not a national research priority. It is a rounding error with a press release.

A household comparison makes the number harder to hide. If an eating disorder professional earns $75,000 per year, the same percentage of her income donated toward eating disorder research would be … five cents.

One nickel.

That is the scale of “the victory” being celebrated.

Nor is the $5 million, in any meaningful scientific sense, $5 million for eating disorder research. Four million dollars is directed to the National Center of Excellence for Eating Disorders. The committee language describes provider engagement, pediatrician consultation, screening and treatment guidance, pediatric training models, prevention, early intervention, treatment protocols, education, training, and awareness. Those functions may be useful. They may improve identification. But they are not longitudinal mortality studies. They are not randomized clinical trials. They are not biological, genetic, neuropsychiatric, pharmacologic, or comparative treatment research at the scale the illness demands.

The remaining $1 million is labeled “Eating Disorders Research” under the HHS Office on Women’s Health. That line is narrow by design. Eating disorders affect women and girls, but they also affect men, boys, athletes, veterans, older adults, and people across race, income, and geography. A serious national research agenda would not be confined to one office, one demographic frame, or one million dollars.

If research means actual NIH scale investigation into causes, mortality, treatment outcomes, relapse, biological mechanisms, clinical standards, access, comparative efficacy, and prevention, then this package does not appear to do that.

Zero dollars in this package are appropriated to the NIH eating disorder research portfolio.

Zero dollars are described as new NIH grants for disease mechanism, clinical trials, longitudinal outcomes, mortality reduction, pharmacologic innovation, or treatment accountability.

Zero Dollars.

That is the headline.

The number becomes worse when placed against eating disorder mortality. ANAD reports that 10,200 deaths each year are the direct result of an eating disorder, roughly one death every 52 minutes. If the entire $5 million package is credited as eating disorder funding, it equals about $490 for each eating disorder death.

That is not valuation. It is scale. It is an insult to those who have died from eating disorders.

If only the $1 million line labeled “Eating Disorders Research” is counted, the figure falls to about $98 per death. If only new NIH research money specifically created by this package is counted, the figure is zero.

That is the damning arithmetic behind the celebration. But there is more.

Eating disorders are not obscure. They affect an estimated 28.8 million Americans over a lifetime. They carry serious medical risk. They intersect with anxiety, depression, trauma, substance use, suicide, cardiac complications, endocrine disruption, gastrointestinal injury, bone loss, infertility, malnutrition, and organ failure. They are not lifestyle problems. They are not boutique illnesses. They are not adolescent vanity disorders. They are lethal psychiatric and medical diseases.

Yet the federal response remains as if eating disorders did not exist at all.

Research disparity among other mental health issues is shocking. NIH estimated eating disorder research support at roughly $55 million in fiscal year 2024. Anxiety disorders received about $266 million. Depression received about $673 million. Schizophrenia received about $239 million. Drug abuse, through NIDA alone, received about $1.663 billion. Substance misuse received about $2.588 billion.

Those conditions deserve serious funding. The comparison does not prove they are overfunded. It proves something else: when the federal government treats a psychiatric or behavioral health condition as a research priority, it knows how to fund at scale.

Eating disorders are not treated that way.

The same point appears in federal spending outside health research. The federal government has been willing to identify, authorize, defend, or fund foreign and international programs in amounts that exceed or dwarf the entire eating disorder package. Publicly cited examples include:

$6 million for cultural tourism and local economic development in Egypt.

$20 million for Ahlan Simsim Iraq, a USAID funded Sesame Workshop affiliated program aimed at children in Iraq.

$24.6 million to build climate resilience in Honduras.

$13.4 million for civic engagement in Zimbabwe.

And nearly $11 million for armored personnel carriers for Uruguay’s quick reaction force. It staggers the imagination to know our federal government is spending more than twice as much on armored personnel carriers for Uruguay’s quick reaction force instead of eating disorder research.

On questionable domestic programs, the federal government has been willing to provide funding in amounts that equal the entire eating disorder package. Publicly cited examples include:

$5 million appropriated for potato breeding facilities in Idaho.

$5 million for historical publications and records grants.

$5 million for Native tourism activities.

$5 million for a harmful algal bloom demonstration program.

$5 million for algal carbon utilization to support data centers.

$5 million for a golden mussel watercraft inspection program in California.

$5 million for moving a local airport passenger terminal in Texas.

$5 million for a veterinary teaching clinic in Kentucky.

Those projects have their lobbyists, their local sponsors, and their bureaucratic justifications. Compared with the federal neglect of eating disorders, they are worthless priorities. They do not carry the mortality burden. They do not explain 10,200 deaths a year. They do not represent a national psychiatric and medical crisis. They do not leave families burying children after years of failed treatment, denied care, and inadequate science.

The comparison is not unfair. It is the point. Five million dollars is a routine federal line item for potatoes, mussels, algae, airports, tourism, records, and veterinary facilities. For eating disorders, it is being sold as a national victory. It is actually a national disgrace.

Washington can move tens of millions of dollars when a priority is visible. It can defend large sums when a program has institutional force behind it. It can spend at scale when the issue is treated as urgent. Eating disorders, despite the mortality burden, remain funded as if the deaths are regrettable but politically inexpensive.

Which brings the focus back to the Eating Disorders Coalition.

The EDCoalition has existed since 2000. After more than a quarter century of organized federal advocacy, the question is not why Congress did so little. The question is why the leading federal eating disorder advocacy organization is celebrating so little and accomplishing even less. Who is funding the EDCoalition for this gross incompetence? For that matter, let’s explore that gross incompetence.

Let us start with the size of the ask. A movement serious about research would not treat a few million dollars as a historic achievement. It would be demanding a major NIH eating disorder initiative, a national mortality study, longitudinal outcomes data, comparative treatment research, relapse studies, treatment safety research, and real accountability for levels of care. It would insist that eating disorders be funded in proportion to their lethality, prevalence, and medical complexity.

Instead, we are left to wonder who is funding the EDCoalition and diverting attention away from those important issues? Who is funding this betrayal of public trust and setting the agenda? Answers to which will never be supplied. Transparency is optional.

Instead, we watch with incredulity EDCoalition celebrating a meaningless $5 million appropriation, most of it directed toward screening, training, education, consultation, early detection, and technical assistance.

Those are support functions. They are not a research agenda.

In some ways, no appropriation at all would have been more honest. Zero dollars would have plainly exposed the neglect. It could have become a legitimate rallying point. Families, clinicians, researchers, and patients could have pointed to the absence and said: this is what abandonment looks like. Why does this exist?

Five million dollars does something more dangerous. It creates the appearance of progress while preserving the reality of neglect. It gives Congress a talking point. It gives advocacy organizations a fundraising headline. It lets the field announce movement without forcing the community to confront how little was actually done.

That is why the celebration is not harmless.

A token appropriation can anesthetize outrage. It allows policymakers to praise families, clinicians, researchers, and people with lived experience while allocating sums that would not sustain a serious national research agenda for one lethal disease. It allows the public to hear that eating disorders received funding without understanding that the funding is microscopic. It allows an advocacy organization founded twenty-five years ago to announce a win instead of admitting that the federal response remains grossly inadequate.

The failure is not that nothing happened.

The failure is that so little happened, and the public was asked to applaud.

If eating disorders are serious, life-threatening illnesses, fund them that way. If early detection saves lives, fund the research that proves what works. If evidence-based treatment matters, fund comparative outcomes, relapse data, mortality studies, program accountability, and treatment safety. If one person dies every 52 minutes, stop pretending $490 per death is a victory.

Five million dollars is not progress at scale. It is not a research commitment. It is not a national response. It is a measure of how little the crisis still matters in federal policy. And apparently, with the lack of public outrage, with the failure to demand answers and accountability, the eating disorder community simply does not care either.

That is the indictment.